Results 31 to 40 of about 13,121 (228)

Novel long‐acting antagonists of muscarinicAChreceptors [PDF]

British Journal of Pharmacology, 2018
Background and PurposeThe aim of this study was to develop potent and long‐acting antagonists of muscarinic ACh receptors. The 4‐hexyloxy and 4‐butyloxy derivatives of 1‐[2‐(4‐oxidobenzoyloxy)ethyl]‐1,2,3,6‐tetrahydropyridin‐1‐ium were synthesized and tested for biological activity.
Alena Randáková, Vladimír Rudajev, Vladimír Doležal, John Boulos, Jan Jakubík   +4 more
openaire   +2 more sources

Corrigendum to "Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium". [PDF]

Biomed Res Int, 2019
[This corrects the article DOI: 10.1155/2018/7473690.].
Hamelmann E.
europepmc   +3 more sources

Optimizing asthma management: Role of long-acting muscarinic antagonists

Journal of Allergy and Clinical Immunology, 2022
Patients with asthma who are suboptimally responsive to inhaled corticosteroids (ICS) and long-acting β2-agonists (LABAs) are frequently exposed to oral corticosteroids and high-dose ICS, which can lead to significant side effects. Long-acting muscarinic antagonists (LAMAs) have demonstrated efficacy and safety in a subset of these patients.
Casale, Thomas B, Foggs, Michael B, Balkissoon, Ronald C   +2 more
openaire   +3 more sources

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma? [PDF]

European Respiratory Review, 2016
Asthma is a chronic inflammatory disorder of the airways that is a major global burden on both individuals and healthcare systems. Despite guideline-directed treatment, a significant proportion of patients with asthma do not achieve control. This review focuses on the potential use of long-acting anticholinergics as bronchodilators in the treatment of ...
Busse, William W, Dahl, Ronald, Jenkins, Christine, Cruz, Alvaro A   +3 more
openaire   +3 more sources

Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea [PDF]

Tuberculosis and Respiratory Diseases, 2021
Background Many chronic obstructive pulmonary disease (COPD) patients receiving monotherapy continue to experience symptoms, exacerbations and poor quality of life.
Sang Haak Lee, Chin Kook Rhee, Kwangha Yoo, Jeong Woong Park, Suk Joong Yong, Jusang Kim, Taehoon Lee, Seong Yong Lim, Ji-Hyun Lee, Hye Yun Park, Minyoung Moon, Ki-Suck Jung   +11 more
doaj   +1 more source

Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases [PDF]

Therapeutic Advances in Chronic Disease, 2014
Acetylcholine (neuronal and non-neuronal origin) regulates bronchoconstriction, and mucus secretion. It has an inflammatory effect by inducing attraction, survival and cytokine release from inflammatory cells. Muscarinic receptors throughout the bronchial tree are mainly restricted to muscarinic M1, M2 and M3 receptors.
Khuder, Alagha, Alain, Palot, Tunde, Sofalvi, Laurie, Pahus, Marion, Gouitaa, Celine, Tummino, Stephanie, Martinez, Denis, Charpin, Arnaud, Bourdin, Pascal, Chanez   +9 more
openaire   +2 more sources

Pembrolizumab-associated bronchiolitis in an elderly lung cancer patient required the treatment with an inhaled corticosteroid, erythromycin and bronchodilators

Respiratory Medicine Case Reports, 2019
Immune checkpoint inhibitors (ICIs) have been used to treat lung cancer. Several types of ICI-related interstitial lung diseases have been reported, including organizing pneumonia, non-specific interstitial pneumonia, and diffuse alveolar damage. However,
Takafumi Yamaya, Hwang Moon Hee, Takayuki Aoyagi, Tatsuya Ogimoto, Naoki Yamada, Ryoichi Ishikawa, Erika Nakai, Kenta Nishi, Chie Yoshimura, Yasuo Nishizaka   +9 more
doaj   +1 more source

Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. [PDF]

, 2011
BACKGROUND: The long-term efficacy and safety of aclidinium bromide, a novel, long-acting muscarinic antagonist, were investigated in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Fabbri, Leonardo M., Caracta, C, Stephen I Rennard, James F Donohue, Caracta, Cynthia, Gil, Esther Garcia, Jones, PW, Donohue, JF, Magnussen, Helgo, Bateman, ED, Nicholas J Gross, Bateman, Eric D, Channez, Pascal, Fabbri, L, Agusti, Alvar, Lamarca R, Gross Nicholas J, Magnussen Helgo, Gil, Esther G, Cynthia Caracta, Caracta Cynthia, Chanez P, Jones, Paul, Agusti Alvar, Paul W Jones, Lamarca, R, Bateman, Eric D., Jones, Paul W., Gross, Nicholas J, Esther Garcia Gil, Agusti A, Gil, Esther, Rosa Lamarca, Alvar Agusti, Jones, Paul W, Chanez, P, Fabbri Leonardo, Magnussen H, Helgo Magnussen, Donohue JF, Gil, EG, Magnussen, H, Donohue James F, Gross, Nicholas J., Garcia Gil, Esther, Jones PW, Rennard, SI, Lamarca, Rosa, Gross NJ, Agusti, A, Caracta C, Eric D Bateman, Jones Paul W, Gil Esther, Chanez, Pascal, Donohue, James F, Donohue, James F., Bateman Eric D, Rennard, Stephen I., Bateman, Eric, Rennard Stephen I, Gross, Nicholas, Gross, NJ, Pascal Chanez, Rennard, Stephen, Bateman ED, Agustí García-Navarro, Àlvar, Lamarca Rosa, Chanez Pascal, Rennard, Stephen I, Rennard SI, Gil EG, Fabbri, Leonardo, Leonardo Fabbri, Donohue, James   +74 more
core   +1 more source

Emerging role of long acting muscarinic antagonists for asthma [PDF]

British Journal of Clinical Pharmacology, 2013
Acetlycholine is involved in the control of airway smooth muscle constriction and in recruitment of inflammatory cells via neuronal and paracrine effects on muscarinic type 3 receptors. Long acting muscarinic antagonists (LAMA) are well established in guidelines for COPD but are not currently licensed for use in asthma. There are emerging data from key
openaire   +3 more sources

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

Data in Brief, 2019
This article contains information on the experimental design and methods on how the safety and tolerability data concerning patients with moderate to very severe chronic obstructive pulmonary disease (COPD) were obtained.
James Donohue, Edward Kerwin, Sanjay Sethi, Brett Haumann, Srikanth Pendyala, Lorna Dean, Chris N. Barnes, Edmund J. Moran, Glenn Crater   +8 more
doaj   +1 more source